52803-61-9

Upstream product

• 824-42-0 2-methoxy-3-methylbenzaldehyde 
• 100-44-7 benzyl chloride 
• 188851-95-8 (2-(benzyloxy)-3-methylphenyl)methanol 
• 424791-13-9 methyl 2-(benzyloxy)-3-methylbenzoate 
• 83-40-9 3-methylsalicylic acid 
• 23287-26-5 3-methylsalicylic acid methyl ester 
• 100-39-0 benzyl bromide 

Downstream Products

• 875109-60-7 (2-Benzyloxy-3-methylphenyl)-(4-methoxyphenyl)methanol 
• 1221065-03-7 dimethyl 2-(2-(benzyloxy)-3-methylbenzylidene)malonate 
• 1335103-11-1 2-(benzyloxy)-1-(bromomethyl)-3-methylbenzene 
• 1335103-13-3 (R)-bis(2-hydroxy-3-methylbenzyl)-[1-(2-hydroxyphenyl)ethyl]amine 
• 1335103-16-6 C₄₅H₄₅NO₃ 
• 188851-95-8 (2-(benzyloxy)-3-methylphenyl)methanol 
• 1453172-77-4 1-(2-(benzyloxy)-3-methylphenyl)-N-methylmethanamine 
• 1453172-79-6 4-(benzyloxy)-5-methyl-2-methylisoindolin-1-one 
• 27992-74-1 2-(4-methoxybenzyl)-6-methylphenol 
• 111637-27-5 tri-(2-hydroxy-3-methylbenzyl)amine 
• 882533-07-5 tris-(2-benzyloxy-3-methyl-benzyl)-amine 

Relevant academic research and scientific papers

Synthesis and structure–activity relationships of aristoyagonine derivatives as brd4 bromodomain inhibitors with x-ray co-crystal research

Epigenetic regulation is known to play a key role in progression of anti-cancer therapeutics. Lysine acetylation is an important mechanism in controlling gene expression. There has been increasing interest in bromodomain owing to its ability to modulate t

Highly Active Multidentate Ligand-Based Alkyne Metathesis Catalysts

Alkyne metathesis catalysts composed of molybdenum(VI) propylidyne and multidentate tris(2-hydroxylbenzyl)methane ligands have been developed, which exhibit excellent stability (remains active in solution for months at room temperature), high activity, an

TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS

Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone derivatives represented by formula (I), pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for treating hyperproliferative disorders by administering the compounds are also described. 1,2,3,4-tetrahydroisoquinoline derivatives for making tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds are also described.

Synthesis of dibenzoxepine lactams via a Cu-catalyzed one-pot etherification/aldol condensation cascade reaction: Application toward the total synthesis of aristoyagonine

A general synthesis of dibenzoxepine lactams has been developed using a one-pot Cu-catalyzed etherification/aldol condensation cascade reaction. The reaction of 4-hydroxyisoindolin-1-one with a wide range of 2-bromobenzaldehydes in the presence of a copper catalyst provided various aristoyagonine derivatives in good yields.

Expeditious synthesis of benzopyrans via lewis acid-catalyzed C-H functionalization: Remarkable enhancement of reactivity by an ortho substituent

An expeditious construction of a benzopyran skeleton via Lewis acid-catalyzed C-H functionalization was achieved. In this process, a [1,5] hydride shift and 6-endo cyclization successively occurred to give benzopyrans. The presence of substituents ortho to the alkoxy group significantly enhanced the reactivity, affording the desired compounds in excellent chemical yields with short reaction times.

NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES

A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

Effective synthesis of ortho-substituted triphenol amines via reductive amination

An efficient synthesis of ortho-substituted triphenolamines via reductive amination is reported. This approach allows access to this increasingly important class of ligands in a structurally systematic way using either commercially or easily synthesizable

Process of producing catechol derivatives

PCT No. PCT/JP96/03650 Sec. 371 Date Jun. 19, 1998 Sec. 102(e) Date Jun. 19, 1998 PCT Filed Dec. 13, 1996 PCT Pub. No. WO97/22574 PCT Pub. Date Jun. 26, 1997An improved process for producing a catechol derivative (1) useful as a intermediate of pharmaceuticals and agricultural chemicals, being shown by the following reaction scheme. The process is characterized in that formulation in the first step is carried out in the two stages, that is, the reaction is carried out in the presence of a tin catalyst at 60-85 DEG C. to a conversion of 30 to 80% and then is completed at 95-105 DEG C. to produce a salicylaldehyde derivative (3) in a high yield and a high selectivity. Thereby, the objective catechol derivative (1) can be obtained in a high yield and with a high purity. In the above formula, R is alkyl, cycloalkyl, aralkyl, alkoxy, halogen atom, allyl, or aryl, and R1 is a hydroxy protective group.